Related Experiment Video
Updated: May 17, 2026
12:52
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
Interleukins in glioblastoma pathophysiology: implications for therapy
Y T Yeung1, K L McDonald, T Grewal
1Faculty of Pharmacy, University of Sydney, Sydney, NSW, Australia.
British Journal of Pharmacology
|October 16, 2012
Summary
Glioblastoma multiforme (GBM) treatment requires novel drugs due to its poor prognosis. Targeting inflammation, crucial in GBM development, presents therapeutic opportunities and challenges.
Area of Science:
- Neuro-oncology
- Cancer immunology
- Drug development
Background:
- Glioblastoma multiforme (GBM) has a poor prognosis, necessitating new therapeutic strategies.
- An inflammatory microenvironment is implicated in GBM initiation and progression.
- Current anti-inflammatory therapies for GBM have shown limited success.
Purpose of the Study:
- To review evidence linking inflammation to glioblastoma pathogenesis.
- To discuss potential anti-inflammatory drug targets for GBM treatment.
- To provide perspective on challenges in developing anti-inflammatory drugs for GBM.
Main Methods:
- Literature review of studies on glioblastoma and inflammation.
- Analysis of the roles of specific cytokines (IL-1β, IL-6, IL-8).
- Evaluation of kinase inhibitors targeting inflammatory signaling pathways (JAK, JNK, p38 MAPK).
Main Results:
- Accumulating evidence supports inflammation's role in GBM development.
- Specific cytokines like IL-1β, IL-6, and IL-8 are key inflammatory mediators.
- Kinase inhibitors targeting JAK, JNK, and p38 MAPK pathways show therapeutic potential.
Conclusions:
- Targeting inflammation is a promising, yet challenging, avenue for GBM therapy.
- Understanding inflammatory pathways is critical for developing effective GBM drugs.
- Further research into anti-inflammatory agents is needed to improve patient outcomes.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...